ArriVent BioPharma, Inc. Common Stock
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of ArriVent BioPharma, Inc. Common Stock generated cash of -$55,842,000, which is less than the previous year. Cash used in financing activities reached the amount of $42,859,000 last year. Net change in cash is therefore -$12,983,000.
Cash Flow
| 2022 | -43.63M | 0 | 169.72M |
|---|---|---|---|
| 2023 | -55.84M | 0 | 42.85M |
AVBP Cash Flow Statement (2022 – 2023)
| 2023 | 2022 | |
|---|---|---|
Cash at beginning of period | 163.37M | 37.28M |
Operating activities | ||
Net income | -69.33M | -36.90M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||
Depreciation and amortization | 0 | 0 |
Stock-based compensation expense | 895K | 424K |
| Deferred income tax benefit | 895K | 424K |
| Changes in operating assets and liabilities: | ||
Accounts receivable, net | 0 | 0 |
Inventories | 0 | 0 |
Accounts payable | 1.37M | 2.8M |
Cash generated by operating activities | -55.84M | -43.63M |
Investing activities | ||
Purchases Of Investments | -25M | 0 |
Investments In Property Plant And Equipment | 0 | 0 |
Acquisitions Net | 0 | 0 |
Cash generated by investing activities | 0 | 0 |
Financing activities | ||
Common Stock Issued | 0 | 2K |
Payments for dividends | 0 | 0 |
Repurchases of common stock | 0 | 0 |
Repayments of term debt | 0 | 0 |
Cash used in financing activities | 42.85M | 169.72M |
Net Change In Cash | -12.98M | 126.09M |
Cash at end of period | 150.38M | 163.37M |